Global Biosimilars Market Size, Share & Industry Trends Analysis Report By Application (Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others), By Type, By Regional Outlook and Forecast, 2022 - 2028

The Global Biosimilars Market size is expected to reach $59 billion by 2028, rising at a market growth of 24.4% CAGR during the forecast period.

Biosimilar medicines are biotherapeutic products that are identical to an approved reference product in terms of quality, safety, and efficacy. Chronic diseases like cancer and autoimmune disorders are treated with biologics. Biologic drug development is an expensive and time-consuming process, but the development of biosimilars saves time & resources by avoiding needless repetition of clinical trials.

Biopharmaceutical brand-name drugs' generic, non-patented chemical & therapeutic equivalents are known as biosimilars or biogenetics. Proteins like enzymes or antibodies, as well as nucleic acids like DNA or RNA, are examples of natural biologic substances. Biopharmaceuticals are synthetic or recombinant versions of these substances. Biogenetics, on the other hand, are not generic biologics because the complicated process of producing biologics prevents there from being a generic form of a biologic.

The prevalence of chronic diseases like diabetes, cancer, and coronary artery diseases as well as the geriatric population is increase all over the world. Additionally, there is a significant increase in number of clinical trials and creative R&D strategies to create advanced drugs. It is anticipated that rising therapeutic applications and increased R&D in the pharmaceutical sector will open up new market opportunities.

COVID-19 Impact Analysis

Lockdowns have been implemented in many nations as a result of the COVID-19 outbreak, it is anticipated that this will have a negative effect on the growth of the biosimilars market. The COVID-19 pandemic made it difficult for the pharmaceutical industry to concentrate on R&D activities, such as the creation of biosimilars. During the pandemic, the entire healthcare sector concentrated on developing life-saving products. Additionally, delays in product approvals, as well as launches brought on by pandemic situations, would limit the growth of the biosimilar market.

Market Growth Factors

Blockbuster Biologics' Patents are About to Expire, and New Indications are Being Investigated

The majority of early biologic drugs lost their patent protection in the last few years, however, many of today's top-selling medications are expected to do the same in the upcoming years. This is opening up new possibilities for biosimilar medicines. Biosimilars that are currently on the market are used to treat a variety of illnesses and conditions, such as rheumatoid arthritis, cancer, psoriasis, infectious diseases, anemia, kidney failure, type 1 & type 2 diabetes, postmenopausal osteoporosis, and disorders of the growth hormone.

Cost-Effectiveness of Biosimilars

Pharmaceutical preparations known as biologic drugs are either created using living organisms, like bacterial and fungi cultures or mouse animal models, or they contain components that were obtained from them. Medical professionals use these drugs a lot to treat their patients. Biosimilars are administered to patients in the same way as their reference biologics and, in terms of clinical efficacy, produce the same therapeutic effects. However, they differ from the original drug in terms of composition because the latter has a patent owned by a pharmaceutical company that prevents other manufacturers from duplicating it while the patent is in effect.

Market Restraining Factors

Challenges Associated With the Manufacturing Process

The creation of biosimilars is a difficult and expensive process that needs a lot of money, technical know-how, scientific standards, clinical trial experience, and quality control procedures. Contrary to the development of generic drugs, manufacturers of biosimilars are obligated to make comparable investments in clinical trials & post-approval safety monitoring programs. The ability to control variability during the manufacturing process, where the final products are comparable to their biological products, is another important challenge in the production of biosimilars.

Application Outlook

Based on application, the biosimilars market is segmented into blood disorders, oncology diseases, chronic & autoimmune diseases and others. In 2021, the chronic & autoimmune disease segment procured a promising revenue share in the biosimilars market. This is because of an increase in product approvals and a rise in demand for cutting-edge treatment. In addition, the demand for biosimilar products is expected to grow in this segment due to an increase in the number of elderly people, a change in lifestyle, and an unhealthy diet.

Type Outlook

On the basis of type, the biosimilars market is fragmented into human growth hormone, erythropoietin, monoclonal antibodies, insulin, granulocyte-colony stimulating factor, and others. In 2021, the monoclonal antibodies segment held the highest revenue share in the biosimilars market. Man-made monoclonal antibodies function similarly to human antibodies in the immune system. Many diseases, such as some forms of cancer, can be treated with monoclonal antibodies. Due to an increase in R&D activities to develop new biosimilars and a rise in the use of monoclonal antibodies for cancer treatment, the demand for biosimilars in this segment would rise.

Biosimilars Market Report Coverage

Report Attribute	Details
Market size value in 2021	USD 13.8 Billion
Market size forecast in 2028	USD 59 Billion
Base Year	2021
Historical Period	2018 to 2020
Forecast Period	2022 to 2028
Revenue Growth Rate	CAGR of 24.4% from 2022 to 2028
Number of Pages	209
Number of Tables	304
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling
Segments covered	Type, Application, Region
Country scope	US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers	Blockbuster Biologics' Patents are About to Expire, and New Indications are Being Investigated Cost-Effectiveness of Biosimilars
Restraints	Challenges Associated With the Manufacturing Process

Regional Outlook

Region wise, the biosimilars market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the biosimilars market with the highest revenue share in 2021. This is because of the rising number of cases of the oncology diseases in Canada. Also, the advanced healthcare infrastructure would support the regional market growth. In addition to this, various initiatives taken by the government coupled with the demand for robust medical facilities by the people in the region having high disposable income are supporting the market growth in this region.

Free Valuable Insights: Global Biosimilars Market size to reach USD 59 Billion by 2028

KBV Cardinal Matrix - Biosimilars Market Competition Analysis

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. and Novartis AG (Sandoz) are the forerunners in the Biosimilars Market. Companies such as Amgen, Inc., Eli Lilly and Company and Fresenius SE & Co. KGaA are some of the key innovators in Biosimilars Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA

Strategies deployed in Biosimilars Market

» Partnerships, Collaborations and Agreements:

• Aug-2022: Pfizer signed an agreement to acquire Global Blood Therapeutics (GBT), a biopharmaceutical company. This acquisition would improve Pfizer’s more than 30-year heritage in rare hematology & reinforces the company’s commitment to SCD by bringing expertise and a leading portfolio and pipeline with the potential to address the full spectrum of critical requirements in this underserved community.
• Jul-2022: Intas Pharmaceuticals partnered with Prestige Biopharma, a Singapore based biopharmaceutical company. Under this partnership, the commercialization of Prestige Biopharma’s bevacizumab biosimilar, would be supplied in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, Thailand, Vietnam, Philippines, Malaysia, Singapore, Indonesia, Kyrgyzstan, Tajikistan. This partnership focused on Intas's long-term strategy and would reinforce its commitment on enhancing access to high-quality biosimilar drugs for cancer patients all over the world.
• Apr-2022: Intas Pharmaceuticals signed an agreement with Axantia Holding (Axantia), a leading pharmaceutical company. Under the terms of this agreement, Axantia would register, hold the marketing authorization and commercialize Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon, and GCC countries. Under this agreement, Axantia would register, hold the marketing authorization & commercialize Ranibizumab in certain territories that Jordan, Saudi Arabia, Iraq, Lebanon, and GCC nations.
• Dec-2021: Dr. Reddy's Laboratories came into a partnership with Prestige BioPharma Ltd, a Singapore-based firm. This partnership aimed at the supply and commercialization of the former's proposed Trastuzumab biosimilar in select countries in Latin America & Southeast Asia. This partnership would help the company combine its established expertise in the area of biosimilars with its commercial strengths and growth ambition in these markets.
• Dec-2021: Eli Lilly and Company collaborated with Regor Therapeutics Group, an international biotech company. Under this collaboration, the companies would discover, develop and commercialize novel therapies for metabolic diseases. The collaboration would provide the opportunity to expand treatment options available to patients suffering from metabolic disorders.
• Dec-2021: Eli Lilly and Company partnered with Innovent Biologics, a world-class biopharmaceutical company. Under this partnership, the companies would the innovative PD-1 inhibitor sintilimab has been successfully included in the updated National Reimbursement Drug List for all approved indications.
• Oct-2021: Eli Lilly and Company came into a partnership with Cipla, an Indian multinational pharmaceutical company. This partnership focused on enhancing the reach of Lilly’s Diabetes products Humalog and Trulicity (Dulaglutide). Under this partnership, Lilly would transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products, Humalog & Trulicity, to Cipla, subject to all regulatory approvals.
• Jul-2021: Intas Pharmaceuticals entered into an agreement with Meiji and Dong-A Socio Holdings, a parent company of Dong-A ST. By this agreement, Intas aimed at commercializing DMB-3115, a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of autoimmune and inflammatory diseases like plaque psoriasis, Crohn's disease & ulcerative colitis.
• Jun-2021: Teva Pharmaceutical partnered with Bioeq AG, a Swiss biopharmaceutical company. This partnership expanded Teva’s biosimilar portfolio & again demonstrated the company’s firm commitment of creating greater access to quality medications to help enhance the lives of more patients.
• Feb-2021: Biocon Biologics partnered with Clinton Health Access Initiative, a global health organization. Through this partnership, Biocon focused on expanding access to lifesaving cancer biosimilars in over 30 countries in Asia & Africa. The partnership aimed at delivering advanced cancer therapies to patients who would require them the most & ensuring equitable access to high-quality biosimilars in low- and middle-income nations.
• Oct-2020: Novartis teamed up with Molecular Partners, a clinical-stage biopharmaceutical company. The collaboration focused on developing, manufacturing, and commercializing Molecular Partners’ anti-COVID-19 DARPin program, which includes two therapeutic candidates, MP0420 and MP0423. Additionally, the collaboration aimed at leveraging Novartis broad expertise in worldwide drug development, regulatory affairs, manufacturing, and commercialization to quickly advance the program in keeping with the unprecedented global urgency created by the pandemic.
• Aug-2020: Teva Pharmaceutical came into partnership with Alvotech, a fully integrated specialty biopharmaceutical company. This partnership aimed to combine Teva’s long-standing commercial presence & extensive infrastructure in the U.S. market with Alvotech’s scientific experience and state-of-the-art biologics manufacturing.

» Product Launches and Product Expansion:

• May-2022: Biocon Biologics released Abevmy, a biosimilar to Roche’s Avastin. This launch focused on adding another world-class biosimilar to the oncology portfolio in Canada, which includes Ogivri (Trastuzumab) and Fulphila (Pegfilgrastim). Also, Abevmy would allow Biocon to expand patient access to another affordable biologic for cancer care.
• Feb-2021: Fresenius Kabi released IDACIO, an adalimumab biosimilar. The drug is available immediately for all indications of reference medicine in the regions of gastroenterology, rheumatology, and dermatology. As a partner to the Canadian health care system, the company is well known for its high-quality standards & manufacturing capabilities and now for biosimilars, the company invested in comprehensive programs that would make the usage of the product seamless for patients & assist physicians in delivering optimal care.
• Apr-2020: Merck released ONTRUZANT, a biosimilar of the reference biologic medicine Herceptin. ONTRUZANT is available in both 150 mg single-dose vials & 420 mg multiple-dose vials. The launch focused on providing adjuvant treatment of HER2 overexpressing node positive or node negative breast cancer as part of a treatment regimen consisting of cyclophosphamide, doxorubicin, and either paclitaxel or docetaxel.
• Jan-2020: Pfizer launched ZIRABEV, RUXIENCE, & TRAZIMERA, three new biosimilars. The medicines would be launched at the lowest Wholesale Acquisition Cost (WAC) among rituximab, bevacizumab, or trastuzumab products presently available in the market, becoming available at a substantially discounted price to the originator product.

» Acquisitions and Mergers:

• Aug-2022: Amgen completed the acquisition of ChemoCentryx, a biopharmaceutical company focused on orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer. This acquisition aimed at enhancing decades-long leadership in inflammation & nephrology with TAVNEOS, transformative, first-in-class treatment for ANCA-associated vasculitis.
• Mar-2022: Fresenius completed the acquisition of mAbxience, a leading international biopharmaceutical company. The acquisition aimed at expanding its business by making cheaper versions of biotechnology drugs that have lost patent protection. Also, the acquisition would further strengthen and leverage Fresenius Kabi's position, as both perfectly complement the company's growth businesses in biopharmaceuticals & medical technology.
• Feb-2022-Feb Biocon Biologics signed an agreement to acquire Viatris, a global pharmaceutical company. The acquisition would create a unique fully integrated, world's leading biosimilars enterprise. The acquisition further would bring together the complementary capabilities & strengths of both partners and prepares the company for the next decade of value creation for all the stakeholders.

» Approvals and Trials:

• Jul-2022: Sandoz got FDA approval for Hyrimoz. The application includes the indications of the refered medicine Humira not protected by orphan exclusivity, which includes rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ulcerative colitis, ankylosing spondylitis, Crohn’s disease, and plaque psoriasis.
• Jun-2022: Amgen got the FDA approval for RIABNI, a biosimilar to Rituxan. This approval would serve as a benefit for adults living with moderate to severe rheumatoid arthritis, a chronic inflammatory joint disease, who now have access to a proven as well as an affordable treatment option.
• May-2022: Teva Pharmaceutical got MHRA approval for ONGAVIA, a ranibizumab biosimilar referencing Genentech’s LUCENTIS. Ranibizumab would inhibit vascular endothelial growth factor (VEGF) that is responsible for the excessive formation of blood vessels in the retina.
• Mar-2022: Fresenius Kabi got approval for European Commission STIMUFEND, a pegfilgrastim biosimilar referencing NEULASTA. STIMUFEND is Fresenius’s first approved molecule in its oncology biosimilar portfolio & second biosimilar approved in Europe. Fresenius also filed its pegfilgrastim biosimilar candidate for regulatory FDA approval and the application is currently under review.

Scope of the Study

Market Segments Covered in the Report:

By Application

• Oncology Diseases
• Blood Disorders
• Chronic & Autoimmune Diseases
• Others

By Type

• Monoclonal Antibodies
• Granulocyte-Colony Stimulating Factor
• Erythropoietin
• Human Growth Hormone
• Insulin
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Amgen, Inc.
• Biocon Limited
• Dr. Reddy’s Laboratories Ltd.
• Eli Lilly and Company
• Intas Pharmaceutical Ltd
• Novartis AG (Sandoz)
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Fresenius SE & Co. KGaA

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Biosimilars Market, by Application
1.4.2 Global Biosimilars Market, by Type
1.4.3 Global Biosimilars Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jun – 2022, Aug) Leading Players

Chapter 4. Global Biosimilars Market by Application
4.1 Global Oncology Diseases Market by Region
4.2 Global Blood Disorders Market by Region
4.3 Global Chronic & Autoimmune Diseases Market by Region
4.4 Global Others Market by Region

Chapter 5. Global Biosimilars Market by Type
5.1 Global Monoclonal Antibodies Market by Region
5.2 Global Granulocyte-Colony Stimulating Factor Market by Region
5.3 Global Erythropoietin Market by Region
5.4 Global Human Growth Hormone Market by Region
5.5 Global Insulin Market by Region
5.6 Global Others Market by Region

Chapter 6. Global Biosimilars Market by Region
6.1 North America Biosimilars Market
6.1.1 North America Biosimilars Market by Application
6.1.1.1 North America Oncology Diseases Market by Country
6.1.1.2 North America Blood Disorders Market by Country
6.1.1.3 North America Chronic & Autoimmune Diseases Market by Country
6.1.1.4 North America Others Market by Country
6.1.2 North America Biosimilars Market by Type
6.1.2.1 North America Monoclonal Antibodies Market by Country
6.1.2.2 North America Granulocyte-Colony Stimulating Factor Market by Country
6.1.2.3 North America Erythropoietin Market by Country
6.1.2.4 North America Human Growth Hormone Market by Country
6.1.2.5 North America Insulin Market by Country
6.1.2.6 North America Others Market by Country
6.1.3 North America Biosimilars Market by Country
6.1.3.1 US Biosimilars Market
6.1.3.1.1 US Biosimilars Market by Application
6.1.3.1.2 US Biosimilars Market by Type
6.1.3.2 Canada Biosimilars Market
6.1.3.2.1 Canada Biosimilars Market by Application
6.1.3.2.2 Canada Biosimilars Market by Type
6.1.3.3 Mexico Biosimilars Market
6.1.3.3.1 Mexico Biosimilars Market by Application
6.1.3.3.2 Mexico Biosimilars Market by Type
6.1.3.4 Rest of North America Biosimilars Market
6.1.3.4.1 Rest of North America Biosimilars Market by Application
6.1.3.4.2 Rest of North America Biosimilars Market by Type
6.2 Europe Biosimilars Market
6.2.1 Europe Biosimilars Market by Application
6.2.1.1 Europe Oncology Diseases Market by Country
6.2.1.2 Europe Blood Disorders Market by Country
6.2.1.3 Europe Chronic & Autoimmune Diseases Market by Country
6.2.1.4 Europe Others Market by Country
6.2.2 Europe Biosimilars Market by Type
6.2.2.1 Europe Monoclonal Antibodies Market by Country
6.2.2.2 Europe Granulocyte-Colony Stimulating Factor Market by Country
6.2.2.3 Europe Erythropoietin Market by Country
6.2.2.4 Europe Human Growth Hormone Market by Country
6.2.2.5 Europe Insulin Market by Country
6.2.2.6 Europe Others Market by Country
6.2.3 Europe Biosimilars Market by Country
6.2.3.1 Germany Biosimilars Market
6.2.3.1.1 Germany Biosimilars Market by Application
6.2.3.1.2 Germany Biosimilars Market by Type
6.2.3.2 UK Biosimilars Market
6.2.3.2.1 UK Biosimilars Market by Application
6.2.3.2.2 UK Biosimilars Market by Type
6.2.3.3 France Biosimilars Market
6.2.3.3.1 France Biosimilars Market by Application
6.2.3.3.2 France Biosimilars Market by Type
6.2.3.4 Russia Biosimilars Market
6.2.3.4.1 Russia Biosimilars Market by Application
6.2.3.4.2 Russia Biosimilars Market by Type
6.2.3.5 Spain Biosimilars Market
6.2.3.5.1 Spain Biosimilars Market by Application
6.2.3.5.2 Spain Biosimilars Market by Type
6.2.3.6 Italy Biosimilars Market
6.2.3.6.1 Italy Biosimilars Market by Application
6.2.3.6.2 Italy Biosimilars Market by Type
6.2.3.7 Rest of Europe Biosimilars Market
6.2.3.7.1 Rest of Europe Biosimilars Market by Application
6.2.3.7.2 Rest of Europe Biosimilars Market by Type
6.3 Asia Pacific Biosimilars Market
6.3.1 Asia Pacific Biosimilars Market by Application
6.3.1.1 Asia Pacific Oncology Diseases Market by Country
6.3.1.2 Asia Pacific Blood Disorders Market by Country
6.3.1.3 Asia Pacific Chronic & Autoimmune Diseases Market by Country
6.3.1.4 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Biosimilars Market by Type
6.3.2.1 Asia Pacific Monoclonal Antibodies Market by Country
6.3.2.2 Asia Pacific Granulocyte-Colony Stimulating Factor Market by Country
6.3.2.3 Asia Pacific Erythropoietin Market by Country
6.3.2.4 Asia Pacific Human Growth Hormone Market by Country
6.3.2.5 Asia Pacific Insulin Market by Country
6.3.2.6 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Biosimilars Market by Country
6.3.3.1 China Biosimilars Market
6.3.3.1.1 China Biosimilars Market by Application
6.3.3.1.2 China Biosimilars Market by Type
6.3.3.2 Japan Biosimilars Market
6.3.3.2.1 Japan Biosimilars Market by Application
6.3.3.2.2 Japan Biosimilars Market by Type
6.3.3.3 India Biosimilars Market
6.3.3.3.1 India Biosimilars Market by Application
6.3.3.3.2 India Biosimilars Market by Type
6.3.3.4 South Korea Biosimilars Market
6.3.3.4.1 South Korea Biosimilars Market by Application
6.3.3.4.2 South Korea Biosimilars Market by Type
6.3.3.5 Singapore Biosimilars Market
6.3.3.5.1 Singapore Biosimilars Market by Application
6.3.3.5.2 Singapore Biosimilars Market by Type
6.3.3.6 Malaysia Biosimilars Market
6.3.3.6.1 Malaysia Biosimilars Market by Application
6.3.3.6.2 Malaysia Biosimilars Market by Type
6.3.3.7 Rest of Asia Pacific Biosimilars Market
6.3.3.7.1 Rest of Asia Pacific Biosimilars Market by Application
6.3.3.7.2 Rest of Asia Pacific Biosimilars Market by Type
6.4 LAMEA Biosimilars Market
6.4.1 LAMEA Biosimilars Market by Application
6.4.1.1 LAMEA Oncology Diseases Market by Country
6.4.1.2 LAMEA Blood Disorders Market by Country
6.4.1.3 LAMEA Chronic & Autoimmune Diseases Market by Country
6.4.1.4 LAMEA Others Market by Country
6.4.2 LAMEA Biosimilars Market by Type
6.4.2.1 LAMEA Monoclonal Antibodies Market by Country
6.4.2.2 LAMEA Granulocyte-Colony Stimulating Factor Market by Country
6.4.2.3 LAMEA Erythropoietin Market by Country
6.4.2.4 LAMEA Human Growth Hormone Market by Country
6.4.2.5 LAMEA Insulin Market by Country
6.4.2.6 LAMEA Others Market by Country
6.4.3 LAMEA Biosimilars Market by Country
6.4.3.1 Brazil Biosimilars Market
6.4.3.1.1 Brazil Biosimilars Market by Application
6.4.3.1.2 Brazil Biosimilars Market by Type
6.4.3.2 Argentina Biosimilars Market
6.4.3.2.1 Argentina Biosimilars Market by Application
6.4.3.2.2 Argentina Biosimilars Market by Type
6.4.3.3 UAE Biosimilars Market
6.4.3.3.1 UAE Biosimilars Market by Application
6.4.3.3.2 UAE Biosimilars Market by Type
6.4.3.4 Saudi Arabia Biosimilars Market
6.4.3.4.1 Saudi Arabia Biosimilars Market by Application
6.4.3.4.2 Saudi Arabia Biosimilars Market by Type
6.4.3.5 South Africa Biosimilars Market
6.4.3.5.1 South Africa Biosimilars Market by Application
6.4.3.5.2 South Africa Biosimilars Market by Type
6.4.3.6 Nigeria Biosimilars Market
6.4.3.6.1 Nigeria Biosimilars Market by Application
6.4.3.6.2 Nigeria Biosimilars Market by Type
6.4.3.7 Rest of LAMEA Biosimilars Market
6.4.3.7.1 Rest of LAMEA Biosimilars Market by Application
6.4.3.7.2 Rest of LAMEA Biosimilars Market by Type

Chapter 7. Company Profiles
7.1 Fresenius SE & Co. KGaA
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.1.5.2 Product Launches and Product Expansions:
7.1.5.3 Acquisition and Mergers:
7.2 Dr. Reddy’s Laboratories Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.3.5.2 Product Launches and Product Expansions:
7.3.5.3 Acquisition and Mergers:
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Product Launches and Product Expansions:
7.4.5.3 Acquisition and Mergers:
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Approvals and Trials:
7.5.5.3 Product Launches and Product Expansions:
7.6 Eli Lilly And Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 Merck & Co., Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.8 Novartis AG (Sandoz)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.9 Biocon Limited
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Partnerships, Collaborations, and Agreements:
7.9.2.2 Product Launches and Product Expansions:
7.9.2.3 Acquisition and Mergers:
7.10. Intas Pharmaceutical Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
7.10.2.2 Product Launches and Product Expansions:

TABLE 1 Global Biosimilars Market, 2018 - 2021, USD Million
TABLE 2 Global Biosimilars Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Biosimilars Market
TABLE 4 Product Launches And Product Expansions– Biosimilars Market
TABLE 5 Acquisition and Mergers– Biosimilars Market
TABLE 6 Approvals and Trials – Biosimilars Market
TABLE 7 Global Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 8 Global Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 9 Global Oncology Diseases Market by Region, 2018 - 2021, USD Million
TABLE 10 Global Oncology Diseases Market by Region, 2022 - 2028, USD Million
TABLE 11 Global Blood Disorders Market by Region, 2018 - 2021, USD Million
TABLE 12 Global Blood Disorders Market by Region, 2022 - 2028, USD Million
TABLE 13 Global Chronic & Autoimmune Diseases Market by Region, 2018 - 2021, USD Million
TABLE 14 Global Chronic & Autoimmune Diseases Market by Region, 2022 - 2028, USD Million
TABLE 15 Global Others Market by Region, 2018 - 2021, USD Million
TABLE 16 Global Others Market by Region, 2022 - 2028, USD Million
TABLE 17 Global Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 18 Global Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 19 Global Monoclonal Antibodies Market by Region, 2018 - 2021, USD Million
TABLE 20 Global Monoclonal Antibodies Market by Region, 2022 - 2028, USD Million
TABLE 21 Global Granulocyte-Colony Stimulating Factor Market by Region, 2018 - 2021, USD Million
TABLE 22 Global Granulocyte-Colony Stimulating Factor Market by Region, 2022 - 2028, USD Million
TABLE 23 Global Erythropoietin Market by Region, 2018 - 2021, USD Million
TABLE 24 Global Erythropoietin Market by Region, 2022 - 2028, USD Million
TABLE 25 Global Human Growth Hormone Market by Region, 2018 - 2021, USD Million
TABLE 26 Global Human Growth Hormone Market by Region, 2022 - 2028, USD Million
TABLE 27 Global Insulin Market by Region, 2018 - 2021, USD Million
TABLE 28 Global Insulin Market by Region, 2022 - 2028, USD Million
TABLE 29 Global Others Market by Region, 2018 - 2021, USD Million
TABLE 30 Global Others Market by Region, 2022 - 2028, USD Million
TABLE 31 Global Biosimilars Market by Region, 2018 - 2021, USD Million
TABLE 32 Global Biosimilars Market by Region, 2022 - 2028, USD Million
TABLE 33 North America Biosimilars Market, 2018 - 2021, USD Million
TABLE 34 North America Biosimilars Market, 2022 - 2028, USD Million
TABLE 35 North America Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 36 North America Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 37 North America Oncology Diseases Market by Country, 2018 - 2021, USD Million
TABLE 38 North America Oncology Diseases Market by Country, 2022 - 2028, USD Million
TABLE 39 North America Blood Disorders Market by Country, 2018 - 2021, USD Million
TABLE 40 North America Blood Disorders Market by Country, 2022 - 2028, USD Million
TABLE 41 North America Chronic & Autoimmune Diseases Market by Country, 2018 - 2021, USD Million
TABLE 42 North America Chronic & Autoimmune Diseases Market by Country, 2022 - 2028, USD Million
TABLE 43 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 44 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 45 North America Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 46 North America Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 47 North America Monoclonal Antibodies Market by Country, 2018 - 2021, USD Million
TABLE 48 North America Monoclonal Antibodies Market by Country, 2022 - 2028, USD Million
TABLE 49 North America Granulocyte-Colony Stimulating Factor Market by Country, 2018 - 2021, USD Million
TABLE 50 North America Granulocyte-Colony Stimulating Factor Market by Country, 2022 - 2028, USD Million
TABLE 51 North America Erythropoietin Market by Country, 2018 - 2021, USD Million
TABLE 52 North America Erythropoietin Market by Country, 2022 - 2028, USD Million
TABLE 53 North America Human Growth Hormone Market by Country, 2018 - 2021, USD Million
TABLE 54 North America Human Growth Hormone Market by Country, 2022 - 2028, USD Million
TABLE 55 North America Insulin Market by Country, 2018 - 2021, USD Million
TABLE 56 North America Insulin Market by Country, 2022 - 2028, USD Million
TABLE 57 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 58 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 59 North America Biosimilars Market by Country, 2018 - 2021, USD Million
TABLE 60 North America Biosimilars Market by Country, 2022 - 2028, USD Million
TABLE 61 US Biosimilars Market, 2018 - 2021, USD Million
TABLE 62 US Biosimilars Market, 2022 - 2028, USD Million
TABLE 63 US Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 64 US Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 65 US Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 66 US Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 67 Canada Biosimilars Market, 2018 - 2021, USD Million
TABLE 68 Canada Biosimilars Market, 2022 - 2028, USD Million
TABLE 69 Canada Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 70 Canada Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 71 Canada Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 72 Canada Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 73 Mexico Biosimilars Market, 2018 - 2021, USD Million
TABLE 74 Mexico Biosimilars Market, 2022 - 2028, USD Million
TABLE 75 Mexico Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 76 Mexico Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 77 Mexico Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 78 Mexico Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 79 Rest of North America Biosimilars Market, 2018 - 2021, USD Million
TABLE 80 Rest of North America Biosimilars Market, 2022 - 2028, USD Million
TABLE 81 Rest of North America Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 82 Rest of North America Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 83 Rest of North America Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 84 Rest of North America Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 85 Europe Biosimilars Market, 2018 - 2021, USD Million
TABLE 86 Europe Biosimilars Market, 2022 - 2028, USD Million
TABLE 87 Europe Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 88 Europe Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 89 Europe Oncology Diseases Market by Country, 2018 - 2021, USD Million
TABLE 90 Europe Oncology Diseases Market by Country, 2022 - 2028, USD Million
TABLE 91 Europe Blood Disorders Market by Country, 2018 - 2021, USD Million
TABLE 92 Europe Blood Disorders Market by Country, 2022 - 2028, USD Million
TABLE 93 Europe Chronic & Autoimmune Diseases Market by Country, 2018 - 2021, USD Million
TABLE 94 Europe Chronic & Autoimmune Diseases Market by Country, 2022 - 2028, USD Million
TABLE 95 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 96 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 97 Europe Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 98 Europe Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 99 Europe Monoclonal Antibodies Market by Country, 2018 - 2021, USD Million
TABLE 100 Europe Monoclonal Antibodies Market by Country, 2022 - 2028, USD Million
TABLE 101 Europe Granulocyte-Colony Stimulating Factor Market by Country, 2018 - 2021, USD Million
TABLE 102 Europe Granulocyte-Colony Stimulating Factor Market by Country, 2022 - 2028, USD Million
TABLE 103 Europe Erythropoietin Market by Country, 2018 - 2021, USD Million
TABLE 104 Europe Erythropoietin Market by Country, 2022 - 2028, USD Million
TABLE 105 Europe Human Growth Hormone Market by Country, 2018 - 2021, USD Million
TABLE 106 Europe Human Growth Hormone Market by Country, 2022 - 2028, USD Million
TABLE 107 Europe Insulin Market by Country, 2018 - 2021, USD Million
TABLE 108 Europe Insulin Market by Country, 2022 - 2028, USD Million
TABLE 109 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 110 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 111 Europe Biosimilars Market by Country, 2018 - 2021, USD Million
TABLE 112 Europe Biosimilars Market by Country, 2022 - 2028, USD Million
TABLE 113 Germany Biosimilars Market, 2018 - 2021, USD Million
TABLE 114 Germany Biosimilars Market, 2022 - 2028, USD Million
TABLE 115 Germany Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 116 Germany Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 117 Germany Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 118 Germany Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 119 UK Biosimilars Market, 2018 - 2021, USD Million
TABLE 120 UK Biosimilars Market, 2022 - 2028, USD Million
TABLE 121 UK Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 122 UK Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 123 UK Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 124 UK Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 125 France Biosimilars Market, 2018 - 2021, USD Million
TABLE 126 France Biosimilars Market, 2022 - 2028, USD Million
TABLE 127 France Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 128 France Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 129 France Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 130 France Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 131 Russia Biosimilars Market, 2018 - 2021, USD Million
TABLE 132 Russia Biosimilars Market, 2022 - 2028, USD Million
TABLE 133 Russia Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 134 Russia Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 135 Russia Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 136 Russia Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 137 Spain Biosimilars Market, 2018 - 2021, USD Million
TABLE 138 Spain Biosimilars Market, 2022 - 2028, USD Million
TABLE 139 Spain Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 140 Spain Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 141 Spain Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 142 Spain Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 143 Italy Biosimilars Market, 2018 - 2021, USD Million
TABLE 144 Italy Biosimilars Market, 2022 - 2028, USD Million
TABLE 145 Italy Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 146 Italy Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 147 Italy Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 148 Italy Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 149 Rest of Europe Biosimilars Market, 2018 - 2021, USD Million
TABLE 150 Rest of Europe Biosimilars Market, 2022 - 2028, USD Million
TABLE 151 Rest of Europe Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 152 Rest of Europe Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 153 Rest of Europe Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 154 Rest of Europe Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 155 Asia Pacific Biosimilars Market, 2018 - 2021, USD Million
TABLE 156 Asia Pacific Biosimilars Market, 2022 - 2028, USD Million
TABLE 157 Asia Pacific Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 158 Asia Pacific Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 159 Asia Pacific Oncology Diseases Market by Country, 2018 - 2021, USD Million
TABLE 160 Asia Pacific Oncology Diseases Market by Country, 2022 - 2028, USD Million
TABLE 161 Asia Pacific Blood Disorders Market by Country, 2018 - 2021, USD Million
TABLE 162 Asia Pacific Blood Disorders Market by Country, 2022 - 2028, USD Million
TABLE 163 Asia Pacific Chronic & Autoimmune Diseases Market by Country, 2018 - 2021, USD Million
TABLE 164 Asia Pacific Chronic & Autoimmune Diseases Market by Country, 2022 - 2028, USD Million
TABLE 165 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 166 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 167 Asia Pacific Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 168 Asia Pacific Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 169 Asia Pacific Monoclonal Antibodies Market by Country, 2018 - 2021, USD Million
TABLE 170 Asia Pacific Monoclonal Antibodies Market by Country, 2022 - 2028, USD Million
TABLE 171 Asia Pacific Granulocyte-Colony Stimulating Factor Market by Country, 2018 - 2021, USD Million
TABLE 172 Asia Pacific Granulocyte-Colony Stimulating Factor Market by Country, 2022 - 2028, USD Million
TABLE 173 Asia Pacific Erythropoietin Market by Country, 2018 - 2021, USD Million
TABLE 174 Asia Pacific Erythropoietin Market by Country, 2022 - 2028, USD Million
TABLE 175 Asia Pacific Human Growth Hormone Market by Country, 2018 - 2021, USD Million
TABLE 176 Asia Pacific Human Growth Hormone Market by Country, 2022 - 2028, USD Million
TABLE 177 Asia Pacific Insulin Market by Country, 2018 - 2021, USD Million
TABLE 178 Asia Pacific Insulin Market by Country, 2022 - 2028, USD Million
TABLE 179 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 180 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 181 Asia Pacific Biosimilars Market by Country, 2018 - 2021, USD Million
TABLE 182 Asia Pacific Biosimilars Market by Country, 2022 - 2028, USD Million
TABLE 183 China Biosimilars Market, 2018 - 2021, USD Million
TABLE 184 China Biosimilars Market, 2022 - 2028, USD Million
TABLE 185 China Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 186 China Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 187 China Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 188 China Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 189 Japan Biosimilars Market, 2018 - 2021, USD Million
TABLE 190 Japan Biosimilars Market, 2022 - 2028, USD Million
TABLE 191 Japan Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 192 Japan Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 193 Japan Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 194 Japan Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 195 India Biosimilars Market, 2018 - 2021, USD Million
TABLE 196 India Biosimilars Market, 2022 - 2028, USD Million
TABLE 197 India Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 198 India Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 199 India Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 200 India Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 201 South Korea Biosimilars Market, 2018 - 2021, USD Million
TABLE 202 South Korea Biosimilars Market, 2022 - 2028, USD Million
TABLE 203 South Korea Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 204 South Korea Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 205 South Korea Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 206 South Korea Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 207 Singapore Biosimilars Market, 2018 - 2021, USD Million
TABLE 208 Singapore Biosimilars Market, 2022 - 2028, USD Million
TABLE 209 Singapore Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 210 Singapore Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 211 Singapore Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 212 Singapore Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 213 Malaysia Biosimilars Market, 2018 - 2021, USD Million
TABLE 214 Malaysia Biosimilars Market, 2022 - 2028, USD Million
TABLE 215 Malaysia Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 216 Malaysia Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 217 Malaysia Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 218 Malaysia Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 219 Rest of Asia Pacific Biosimilars Market, 2018 - 2021, USD Million
TABLE 220 Rest of Asia Pacific Biosimilars Market, 2022 - 2028, USD Million
TABLE 221 Rest of Asia Pacific Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 222 Rest of Asia Pacific Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 223 Rest of Asia Pacific Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 224 Rest of Asia Pacific Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 225 LAMEA Biosimilars Market, 2018 - 2021, USD Million
TABLE 226 LAMEA Biosimilars Market, 2022 - 2028, USD Million
TABLE 227 LAMEA Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 228 LAMEA Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 229 LAMEA Oncology Diseases Market by Country, 2018 - 2021, USD Million
TABLE 230 LAMEA Oncology Diseases Market by Country, 2022 - 2028, USD Million
TABLE 231 LAMEA Blood Disorders Market by Country, 2018 - 2021, USD Million
TABLE 232 LAMEA Blood Disorders Market by Country, 2022 - 2028, USD Million
TABLE 233 LAMEA Chronic & Autoimmune Diseases Market by Country, 2018 - 2021, USD Million
TABLE 234 LAMEA Chronic & Autoimmune Diseases Market by Country, 2022 - 2028, USD Million
TABLE 235 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 236 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 237 LAMEA Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 238 LAMEA Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 239 LAMEA Monoclonal Antibodies Market by Country, 2018 - 2021, USD Million
TABLE 240 LAMEA Monoclonal Antibodies Market by Country, 2022 - 2028, USD Million
TABLE 241 LAMEA Granulocyte-Colony Stimulating Factor Market by Country, 2018 - 2021, USD Million
TABLE 242 LAMEA Granulocyte-Colony Stimulating Factor Market by Country, 2022 - 2028, USD Million
TABLE 243 LAMEA Erythropoietin Market by Country, 2018 - 2021, USD Million
TABLE 244 LAMEA Erythropoietin Market by Country, 2022 - 2028, USD Million
TABLE 245 LAMEA Human Growth Hormone Market by Country, 2018 - 2021, USD Million
TABLE 246 LAMEA Human Growth Hormone Market by Country, 2022 - 2028, USD Million
TABLE 247 LAMEA Insulin Market by Country, 2018 - 2021, USD Million
TABLE 248 LAMEA Insulin Market by Country, 2022 - 2028, USD Million
TABLE 249 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 250 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 251 LAMEA Biosimilars Market by Country, 2018 - 2021, USD Million
TABLE 252 LAMEA Biosimilars Market by Country, 2022 - 2028, USD Million
TABLE 253 Brazil Biosimilars Market, 2018 - 2021, USD Million
TABLE 254 Brazil Biosimilars Market, 2022 - 2028, USD Million
TABLE 255 Brazil Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 256 Brazil Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 257 Brazil Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 258 Brazil Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 259 Argentina Biosimilars Market, 2018 - 2021, USD Million
TABLE 260 Argentina Biosimilars Market, 2022 - 2028, USD Million
TABLE 261 Argentina Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 262 Argentina Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 263 Argentina Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 264 Argentina Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 265 UAE Biosimilars Market, 2018 - 2021, USD Million
TABLE 266 UAE Biosimilars Market, 2022 - 2028, USD Million
TABLE 267 UAE Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 268 UAE Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 269 UAE Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 270 UAE Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 271 Saudi Arabia Biosimilars Market, 2018 - 2021, USD Million
TABLE 272 Saudi Arabia Biosimilars Market, 2022 - 2028, USD Million
TABLE 273 Saudi Arabia Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 274 Saudi Arabia Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 275 Saudi Arabia Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 276 Saudi Arabia Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 277 South Africa Biosimilars Market, 2018 - 2021, USD Million
TABLE 278 South Africa Biosimilars Market, 2022 - 2028, USD Million
TABLE 279 South Africa Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 280 South Africa Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 281 South Africa Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 282 South Africa Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 283 Nigeria Biosimilars Market, 2018 - 2021, USD Million
TABLE 284 Nigeria Biosimilars Market, 2022 - 2028, USD Million
TABLE 285 Nigeria Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 286 Nigeria Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 287 Nigeria Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 288 Nigeria Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 289 Rest of LAMEA Biosimilars Market, 2018 - 2021, USD Million
TABLE 290 Rest of LAMEA Biosimilars Market, 2022 - 2028, USD Million
TABLE 291 Rest of LAMEA Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 292 Rest of LAMEA Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 293 Rest of LAMEA Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 294 Rest of LAMEA Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 295 key information – Fresenius SE & Co. KGaA
TABLE 296 key information – Dr. Reddy’s Laboratories Ltd.
TABLE 297 Key Information – Pfizer, Inc.
TABLE 298 Key Information – Amgen, Inc.
TABLE 299 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 300 Key Information – Eli Lilly And Company
TABLE 301 KEY INFORMATION - MERCK & CO., INC.
TABLE 302 Key Information – Novartis AG
TABLE 303 Key Information – Biocon Limited
TABLE 304 Key Information – Intas Pharmaceutical Ltd.

List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jan – 2022, Aug) Leading Players
FIG 5 Global Biosimilars Market Share by Application, 2021
FIG 6 Global Biosimilars Market Share by Application, 2028
FIG 7 Global Biosimilars Market by Application, 2018 - 2028, USD Million
FIG 8 Global Biosimilars Market Share by Type, 2021
FIG 9 Global Biosimilars Market Share by Type, 2028
FIG 10 Global Biosimilars Market by Type, 2018 - 2028, USD Million
FIG 11 Global Biosimilars Market Share by Region, 2021
FIG 12 Global Biosimilars Market Share by Region, 2028
FIG 13 Global Biosimilars Market by Region, 2018 - 2028, USD Million
FIG 14 Recent strategies and developments: Fresenius SE & Co. KGaA
FIG 15 Recent strategies and developments: Dr. Reddy’s Laboratories Ltd.
FIG 16 Recent strategies and developments: Pfizer, Inc.
FIG 17 Recent strategies and developments: Amgen, Inc.
FIG 18 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 19 Recent strategies and developments: Novartis AG
FIG 20 Recent strategies and developments: Biocon Limited
FIG 21 Recent strategies and developments: Intas Pharmaceutical Ltd.